FZD1 appears to mediate drug resistance by modulating the Wnt/β-catenin pathway in clear cell renal cell carcinoma [25], neuroblastoma [59], pancreatic ductal adenocarcinoma [27], ovarian cancer [60], and breast cancer [61]. Here, FZD1 is linked to breast cancer.